Versameb to Present during World Continence Week 2022
- Lead therapeutic candidate has the potential to treat Stress Urinary Incontinence
- Raising awareness of the high unmet medical need of patients
Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, VMB-100, for the treatment of Stress Urinary Incontinence (SUI) at World Continence Week (WCW) 20-26 June 2022. WCW is an annual initiative fully endorsed by the European Association of Urology (EAU) and the International Continence Society (ICS) set up by the World Federation of Incontinence and Pelvic Problems (WFIPP) to raise awareness of bladder & bowel issues, chronic pelvic pain and other debilitating conditions which impact the lives of millions of patients worldwide.